Novel approaches in oncology at AstraZeneca

European Journal of Cancer, Supplement

Volumn 1, Issue 8 SPEC. ISS., 2003, Pages 3-8

  Wheeler, Catherine ^a   Stephens, Trevor ^a   Byth, Kate ^a   Green, Tim ^a   Wedge, Steve ^a   Blakey, David ^a   Hughes, Andrew ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Antiangiogenesis; AZD0530; AZD2171; AZD3409; AZD5438; Vascular targeting; ZD6126; ZD6474

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AZD 0530; AZD 3409; AZD 5438; CISPLATIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; N ACETYLCOLCHINOL PHOSPHATE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VANDETANIB;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; DIARRHEA; DRUG POTENCY; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; ONCOLOGY; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TECHNIQUE;

EID: 3543142779     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(03)80014-9     Document Type: Article

References (30)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 285:1971;1182-1186
2. Risau W. Mechanisms of angiogenesis. Nature. 386:1997;671-674
3. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med. 9:2003;669-676
4. Bates D.O., Heald R.I., Curry F.E., Williams B. Vascular endothelial growth factor increases Rana vascular permeability and compliance by different signalling pathways. J Physiol. 533:2001;263-272
5. Dvorak H.F., Detmar M., Claffey K.P., et al. Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol. 107:1995;233-235
6. Ciardiello F., Caputo R., Damiano V., et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res. 9:2003;1546-1556
7. Wedge S.R., Ogilvie D.J., Dukes M., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 62:2002;4645-4655
8. Bruns C.J., Köhl G., Guba M., et al. Anti-angiogenic and anti-tumor activity of a novel VEGFR-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. 2nd ed. Proc Am Assoc Cancer Res. 44:2003;604. (abstract R3041)
9. Matsumori Y., Goto H., Naktaki E., et al. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase activity, inhibits growth of human non-small cell lung cancer metastases that are resistant to treatment with ZD1839. 2nd ed. Proc Am Assoc Cancer Res. 44:2003;9. (abstract R43)
10. Minami H., Ebi H., Tahara M., et al. A Phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors. 2nd ed. Proc Am Soc Clin Oncol. 22:2003;194. (abstract 778)
11. Hurwitz H., Holden S.N., Eckhardt S.G., et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors. 2nd ed. Proc Am Soc Clin Oncol. 21:2002;82a. (abstract 325)
12. Jain R.K. Molecular regulation of vessel maturation. Nat Med. 9:2003;685-693
13. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature. 407:2000;249-257
14. Blakey D.C., Westwood F.R., Walker M., et al. Antitumor activity of the novel vascular-targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res. 8:2002;1974-1983
15. Davis P.D., Dougherty G.J., Blakey D.C., et al. ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res. 62:2002;7247-7253
16. Siemann D.W., Rojiani A.M. Enhancement of radiation therapy by the novel vascular-targeting agent ZD6126. Int J Radiat Oncol Biol Phys. 53:2002;164-171
17. Siemann D.W., Rojiani A.M. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular-targeting agent ZD6126. Int J Radiat Oncol Biol Phys. 54:2002;1512-1517
18. Robinson S.P., McIntyre D.J., Checkley D., et al. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer. 88:2003;1592-1597
19. Biscardi J.S., Ishizawar R.C., Silva C.M., Parsons S.J. Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interaction in breast cancer. Breast Cancer Res. 2:2000;203-210
20. Irby R.B., Yeatman T.J. Role of Src expression and activation in human cancer. Oncogene. 19:2000;5636-5642
21. Dehm S., Senger M.A., Bonham K. SRC transcriptional activation in a subset of human colon cancer cell lines. FEBS Lett. 487:2001;367-371
22. Verbeek B.S., Vroom T.M., Adriaansen-Slot S.S., et al. c-Src protein expression in increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol. 180:1996;383-388
23. Aligayer H., Boyd D.D., Heiss M.M., et al. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer. 94:2002;344-351
24. Frame M.C. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta. 1602:2002;114-130
25. Yezhelyev M., Wagner C., Köhl G., et al. In vivo and in vitro effects of a novel Src tyrosine kinase inhibitor on human pancreatic cancer in a nude mouse model. 2nd ed. Proc Am Assoc Cancer Res. 44:2003;336. (abstract R1718)
26. Li T., Sparano J.A. Inhibiting Ras signaling in the therapy of breast cancer. Clin Breast Cancer. 3:2003;405-416
27. Sebti S.M., Hamilton A.D. Farnesyltransferase and geranylgeranyl- transferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene. 19:2000;6584-6593
28. Stephens T.C., Wardleworth M.J., Zbigniew S., et al. AZD3409, a novel, oral, protein prenylation inhibitor with promising preclinical antitumor activity. 2nd ed. Proc Am Assoc Cancer Res. 44:2003;970. (abstract R4870)
29. Sausville E.A. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol Med. 8:2002;S32-S37
30. Byth K., Geh C., Forder C., et al. Novel cell cycle inhibitors: characterisation in tumour cell lines and normal cycling cells. 2nd ed. Proc Am Assoc Cancer Res. 44:2003;620. (abstract R3124)